[Comment] Artificial intelligence for breast cancer screening: breathtaking results and a word of caution

In The Lancet Oncology, Kristina Lång and colleagues report a prespecified clinical safety analysis of the MASAI trial,1 investigating the use of artificial intelligence (AI) as a supplement to radiologist reading of mammograms in breast cancer screening. Conducted within the Swedish national breast screening programme, participants were randomly assigned (1:1) to either AI-supported screening (intervention group) or standard double reading without AI (control group). In the intervention group, the AI algorithm was used to triage screening mammograms to provide a level of risk of breast cancer from 1 to 10, with 10 having the highest risk.